Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 3/2015

01.03.2015 | Cardiac Magnetic Resonance (E Nagel and V Puntmann, Section Editors)

Deciphering Cardiovascular Disease in Systemic Inflammatory Diseases Using Advanced Magnetic Resonance Imaging

verfasst von: Sophie Mavrogeni, Petros Sfikakis, Theodoros Dimitroulas, George Markousis-Mavrogenis, Genovefa Kolovou, George D. Kitas

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular involvement in systemic inflammatory diseases (SID) is underestimated despite its high mortality and morbidity. SID with cardiovascular involvement includes rheumatoid arthritis and the spondyloarthropathies, systemic lupus erythematosus, systemic vasculitides, inflammatory myopathies, systemic sclerosis, mixed connective tissue diseases (MCTD) and sarcoidosis (SRC). Cardiovascular magnetic resonance (CMR) is of great value in SID because myocardial inflammation, diffuse, subendocardial vasculitis and small scars due to inflammation or myocardial infarction and heart disease acuity can be detected neither by echocardiography nor by nuclear techniques; finally, most patients are unable to exercise adequately, and pharmacologic stress CMR is the best technique for coronary artery and cardiac microvascular disease assessment. However, lack of availability, expertise and high cost constitute serious obstacles for the routine application of CMR in every day practice.
Literatur
1.
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7.CrossRefPubMed
2.
Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70:8–14.CrossRefPubMed
3.
Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas GD. Micro- and macrovascular treatment targets in scleroderma heart disease. Curr Pharm Des. 2014;20(4):536–44.CrossRefPubMed
4.
Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010;39:269–77.CrossRefPubMed
5.
Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.CrossRefPubMed
6.
Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol. 2009;29(10):1702–8.CrossRefPubMed
7.••
Mavrogeni S, Karabela G, Stavropoulos E, Gialafos E, Sfendouraki E, Kyrou L, et al. Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol. 2013;168(4):4333–5. This paper describes the pathophysiologic background in RA with heart failure.CrossRefPubMed
8.
Rozin AP, Hasin T, Toledano K, Guralnik L, Balbir-Gurman A. Seronegative polyarthritis as severe systemic disease. Neth J Med. 2010;68(6):236–41.PubMed
9.
Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology. 2006;45(Supplement 4):iv8–13.CrossRefPubMed
10.
Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging. 2011;4(1):27–33. This paper emphasizes the significance of microvascular disease in SLE with myocardial ischemia in the absence of obstructive coronary artery disease.CrossRefPubMed
11.
O’Neill SG, Woldman S, Bailliard F, Norman W, McEwan J, Isenberg DA, et al. Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus. Ann Rheum Dis. 2009;68:1478–81.CrossRefPubMed
12.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.CrossRefPubMed
13.
Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin N Am. 2014;40(1):11–26.CrossRef
14.
Sunderkötter C, Sindrilaru A. Clinical classification of vasculitis. Eur J Dermatol. 2006;16:114–24.PubMed
15.
Gonzales Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol. 1996;14:373–9.
16.
17.
Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118:2–10.CrossRefPubMed
18.
19.
Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, et al. The diagnosis and classification of mixed connective tissue disease. J Autoimmun. 2014;48–49:46–9.CrossRefPubMed
20.
Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11. This paper documents the clinical significance of late gadolinium enhancement in the prediction of adverse side effects in sarcoidosis.CrossRefPubMed
21.••
Mavrogeni S, Kouranos V, Sfikakis PP, Bratis K, Kitas GD, Manali E, et al. Myocardial stress perfusion-fibrosis imaging pattern in sarcoidosis, assessed by cardiovascular magnetic resonance imaging. Int J Cardiol. 2014;172(2):501–3. This paper documents the multiple faces of heart involvement in sarcoidosis.CrossRefPubMed
22.
Tanasescu C, Jurcut C, Jurcut R, Ginghina C. Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk. Eur J Intern Med. 2009;20:348–54.CrossRefPubMed
23.
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;14:722–32.CrossRef
24.
25.
Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012;41(4):535–44.CrossRefPubMedCentralPubMed
26.
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331–7.CrossRefPubMed
27.
Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2014. doi:10.​1136/​annrheumdis-2013-204024.
28.
Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006;5:331–7.CrossRefPubMed
29.
Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121(10 Suppl 1):S21–31.CrossRefPubMed
30.
Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2011;50(11):2125–39.CrossRef
31.
Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1411–6.CrossRefPubMed
32.
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203–9.CrossRefPubMed
33.
Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95.CrossRefPubMed
34.
Djokovic A, Stojanovich L, Stanisavljevic N, Bisenic V, Radovanovic S, Soldatovic I, et al. Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes? Rheumatol Int. 2013;34:321–7.CrossRefPubMed
35.
Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 2013;27:33–44.CrossRefPubMed
36.
Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis. 2011;70(6):881–3.CrossRefPubMed
37.
Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937–42.PubMed
38.
Douglas KM, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006;65:348–53.CrossRefPubMedCentralPubMed
39.
Chighizola C, Schioppo T, Ingegnoli F, Meroni PL. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis. Curr Vasc Pharmacol. 2012;10:639–46.CrossRefPubMed
40.
Crowson CS, Liao KP, Davis 3rd JM, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622–8.CrossRefPubMedCentralPubMed
41.
Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3412–9.CrossRefPubMed
42.
Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103:3677–83.CrossRefPubMed
43.
El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004;110:399–404.CrossRefPubMed
44.
Roldan C, Joson J, Sharrar J, Qualls C, Sibbitt W. Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study. J Rheumatol. 2010;37:71–8.CrossRefPubMedCentralPubMed
45.
Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51–60.CrossRefPubMed
46.
Kiani AN, Vogel-Claussen J, Magder LS, Petri M. Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol. 2010;37:579–84.CrossRefPubMed
47.
Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic infl ammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009;30:1837–43.CrossRefPubMed
48.
Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation. 2007;116:419–26.CrossRefPubMed
49.
Borba EF, Bonf E, Vinagre CG, Ramires JA, Maranho RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1033–40.CrossRefPubMed
50.
McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009;60:2428–37.CrossRefPubMedCentralPubMed
51.
Mavrogeni S, Dimitroulas T, Kitas GD. Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmun Rev. 2012;12(2):305–12.CrossRefPubMed
52.
Mavrogeni S, Spargias C, Bratis C, Kolovou G, Markussis V, Papadopoulou E, et al. Myocarditis as a precipitating factor for heart failure: evaluation and 1-year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy. Eur J Heart Fail. 2011;13:830–7.CrossRefPubMed
53.
54.
Mavrogeni S, Sfikakis PP, Gialafos E, Karabela G, Stavropoulos E, Sfendouraki E, et al. Diffuse, subendocardial vasculitis. A new entity identified by cardiovascular magnetic resonance and its clinical implications. Int J Cardiol. 2013;168(3):2971–2.CrossRefPubMed
55.
Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis 3rd JM, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56(11):3583–7.CrossRefPubMed
56.
Wright K, Crowson CS, Gabriel SE. Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure. Heart Fail Clin. 2014;10(2):339–52.CrossRefPubMed
57.
Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–20.CrossRefPubMed
58.
Alpaslan M, Onrat E, Evcik D. Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin Rheumatol. 2003;22(2):84–8.CrossRefPubMed
59.
Dimitroulas T, Giannakoulas G, Papadopoulou K, Sfetsios T, Karvounis H, Dimitroula H, et al. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol. 2010;29(9):957–64.CrossRefPubMed
60.
Buss SJ, Wolf D, Korosoglou G, et al. Myocardial left ventricular dysfunction in patients with systemic lupus erythematosus: new insights from tissue Doppler and strain imaging. J Rheumatol. 2010;37(1):79–86.CrossRefPubMed
61.
Sandoo A, Protogerou AD, Hodson J, Smith JP, Zampeli E, Sfikakis PP, et al. The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14(6):R258.CrossRefPubMedCentralPubMed
62.
Mavrogeni S, Bratis K, van Wijk K, Stavropoulos E, Hautemann D, Reiber JH, et al. Myocardial perfusion-fibrosis pattern in systemic sclerosis assessed by cardiac magnetic resonance. Int J Cardiol. 2012;159(3):e56–8.CrossRefPubMed
63.
Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G, et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol. 2010;37:993–9.CrossRefPubMed
64.
Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. Curr Pharm Des. 2012;18(11):1457–64.CrossRefPubMed
65.
Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J. Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis. 2013. doi:10.​1111/​1756-185X.​12191.PubMed
66.
Kobak S, Kalkan S, Kirilmaz B, Orman M, Ercan E. Pulmonary arterial hypertension in patients with Primary Sjögren’s syndrome. Autoimmune Dis. 2014;2014:710401.PubMedCentralPubMed
67.
Chatterjee S. Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum. 2011;41:19–37.CrossRefPubMed
68.
Mavrogeni S, Vassilopoulos D. Is there a place for cardiovascular magnetic resonance imaging in the evaluation of cardiovascular involvement in rheumatic diseases? Semin Arthritis Rheum. 2011;41(3):488–96.CrossRefPubMed
69.
Mavrogeni S, Manoussakis MN, Karagiorga TC, Douskou M, Panagiotakos D, Bournia V, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum. 2009;61(8):1121–9.CrossRefPubMed
70.••
Mavrogeni S, Sfikakis PP, Gialafos E, Bratis K, Karabela G, Stavropoulos E, et al. Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res. 2014;66(1):104–12. This is a study about the CMR pattern of CTDs with typical or atypical cardiac symptoms.CrossRef
71.
Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8(5):390–7.CrossRefPubMed
72.
Mavrogeni S, Manoussakis MN. Myocarditis and subclavian stenosis in Takayasu arteritis. Int J Cardiol. 2011;148(2):223–4.CrossRefPubMed
73.••
Raman SV, Aneja A, Jarjour WN. CMR in inflammatory vasculitis. J Cardiovasc Magn Reson. 2012;14:82. A well documented presentation of CMR techniques in the evaluation of CTDs.CrossRefPubMedCentralPubMed
74.
Greenwood JP, Motwani M, Maredia N, Brown JM, Everett CC, Nixon J, et al. Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the CE-MARC Trial. Circulation. 2013.
75.
Schalla S, Nagel E, Lehmkuhl H, Klein C, Bornstedt A, Schnackenburg B, et al. Comparison of magnetic resonance real-time imaging of LV function with conventional magnetic resonance imaging and echocardiography. Am J Cardiol. 2001;87:95–9.CrossRefPubMed
76.
Giles JT, Malayeri AA, Fernandes V, Post W, Blumenthal RS, Bluemke D, et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum. 2010;62(4):940–51.CrossRefPubMedCentralPubMed
77.
Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford). 2010;49(3):528–35.CrossRef
78.
Nagel E, Lehmkuh HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99:763–70.CrossRefPubMed
79.
Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knusel PR, et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation. 2001;103:2230–5.CrossRefPubMed
80.
Kobayashi Y, Giles JT, Hirano M, Yokoe I, Nakajima Y, Bathon JM, et al. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther. 2010;12(5):R171.CrossRefPubMedCentralPubMed
81.
Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes B, et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60(5):408–20.CrossRefPubMedCentralPubMed
82.
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87.CrossRefPubMedCentralPubMed
83.
Luechinger R, Scwitter J. CMR update. J. Schwitter Switzerland; 2008. pp 30–41.
84.
Mavrogeni S, Bratis K, Sfendouraki E, Papadopoulou E, Kolovou G. Myopericarditis, as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic resonance. Inflamm Allergy Drug Targets. 2013;12(3):206–11.CrossRefPubMed
85.
Mavrogeni S, Bratis K, Markussis V, Spargias C, Papadopoulou E, Papamentzelopoulos S, et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus. 2013;22(1):34–43.CrossRefPubMed
86.
Gouya H, Cabanes L, Mouthon L, Pavie A, Legmann P, Vignaux O. Severe mitral stenosis as the first manifestation of systemic lupus erythematosus in a 20-year-old woman: the value of magnetic resonance imaging in the diagnosis of Libman-Sacks endocarditis. Int J Cardiovasc Imaging. 2014;30:959–60.CrossRefPubMed
87.
Argyropoulou MI, Kiortsis DN, Daskas N, Xydis V, Mavridis A, Efremidis SC, et al. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin Exp Rheumatol. 2003;21(6):794–7.PubMed
88.
Ormseth MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM, Bian A, et al. Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(9):1410–5.CrossRef
89.
Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis I, Baras P, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol. 2004;43(4):649–52.CrossRefPubMed
90.•
Puntmann VO, D’Cruz D, Taylor PC, Hussain T, Indermuhle A, Butzbach B, et al. Contrast enhancement imaging in coronary arteries in SLE. JACC Cardiovasc Imaging. 2012;5(9):962–4. Subclinical lesions accessed by CMR.CrossRefPubMed
91.
Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis I, Varlamis G, et al. Magnetic resonance angiography, function and viability evaluation in patients with Kawasaki disease. J Cardiovasc Magn Reson. 2006;8(3):493–8.CrossRefPubMed
92.
Weckbach S, Findeisen HM, Schoenberg SO, Kramer H, Stark R, Clevert DA, et al. Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/magnetic resonance angiography. Investig Radiol. 2009;44(4):242–50.CrossRef
93.•
Puntmann VO, D’Cruz D, Smith Z, Pastor A, Choong P, Voigt T, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6(2):295–301. The role of Native myocardial T1 mapping in the detection of subclinical cardiomyopathy in SLE.CrossRefPubMed
Metadaten
Titel
Deciphering Cardiovascular Disease in Systemic Inflammatory Diseases Using Advanced Magnetic Resonance Imaging
verfasst von
Sophie Mavrogeni
Petros Sfikakis
Theodoros Dimitroulas
George Markousis-Mavrogenis
Genovefa Kolovou
George D. Kitas
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 3/2015
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-015-9319-z

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen